Integra Therapeutics and Caszyme have been awarded 1€ million grant from Eurostars, the largest funding programme of the European Commission that supports innovative SMEs in developing collaborative transnational projects geared towards the market. Integra Therapeutics is a Spanish biotech company engineering the next generation of gene writing tools to cure genetic diseases.
The funding of the project submitted by Integra Therapeutics and Caszyme will go towards discovery, characterization, and execution of in vivo studies on the 2.0 version of the Integra Therapeutics FiCAT gene-writing platform.
The key difference between FiCAT 1.0 and FiCAT 2.0 will be the addition of novel nucleases discovered by Caszyme, which have different characteristics from the Cas9 nucleases and expand their potential application in advanced therapies. During the execution of the project, Integra Therapeutics and Caszyme will enhance the functionality of novel nucleases in human cells.
The partnership between Integra Therapeutics and Caszyme will allow both companies unite their scientific know-how and technologies.
The project is scheduled to kick off on the 1st of November 2022 and finish at the end of 2025.
The Eurostar programme is part of Horizon Europe and is managed by Eureka with a network of national coordinators from the 37 participating countries.